Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Current Assets: 2010-2025

Historic Current Assets for OptimizeRx (OPRX) over the last 16 years, with Q3 2025 value amounting to $56.3 million.

  • OptimizeRx's Current Assets rose 2006.99% to $56.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $216.1 million, marking a year-over-year increase of 1049.57%. This contributed to the annual value of $54.0 million for FY2024, which is 66.26% down from last year.
  • As of Q3 2025, OptimizeRx's Current Assets stood at $56.3 million, which was up 2006.99% from $54.1 million recorded in Q2 2025.
  • In the past 5 years, OptimizeRx's Current Assets ranged from a high of $115.1 million in Q4 2021 and a low of $46.0 million during Q2 2024
  • Moreover, its 5-year median value for Current Assets was $87.4 million (2023), whereas its average is $80.5 million.
  • Per our database at Business Quant, OptimizeRx's Current Assets skyrocketed by 29793.67% in 2021 and then tumbled by 4957.21% in 2024.
  • Over the past 5 years, OptimizeRx's Current Assets (Quarter) stood at $115.1 million in 2021, then dropped by 14.37% to $98.6 million in 2022, then plummeted by 44.88% to $54.3 million in 2023, then fell by 0.66% to $54.0 million in 2024, then grew by 4.35% to $56.3 million in 2025.
  • Its last three reported values are $56.3 million in Q3 2025, $54.1 million for Q2 2025, and $51.7 million during Q1 2025.